


Manage TB
Dr. C. Padmapriyadarshini
National Institute for Research in Tuberculosis, Chennai

Lecture – 54
Newer Anti-TB drugs and regimens Session 1

Hello I am Dr. Padmapriya and I would like to discuss a Newer Anti -TB drugs and regimens in the next 2 sessions.

(Refer Slide Time: 00:21)



The slide content is as follows:

Current TB Drug Therapy

DS-TB : 6 - 8 months of treatment
DR-TB : 18-24 months of daily treatment

Shorter regimens:


- Reduce the burden of treatment for patients and health system
- Feasible to increase global coverage with DOT
- Higher treatment completion & cure rates
- Improve TB control
- Drug resistance
- HIV epidemic

The slide also features a vertical logo on the left for 'National Institute for Research in Tuberculosis (NIRT)' and a photograph of Dr. C. Padmapriyadarshini on the right.

What is the need for new TB drugs? Current anti TB therapy for drug sensitive TB varies for 6 to 8 months of treatment and for drug resistant TB it is for 18 to 24 months and it consists of daily regimen for drug resistant TB patients. Now, is there a need for shorter duration of treatment?

Now, shorter regimens will not only reduce the burden of treatment for patients as well as the healthcare system. It will also help us reach the target for directly observed therapy and thus increase the global coverage. There will be higher treatment completion rate as well as cure rate, and thus improving the TB control and reducing the drug resistance especially in the era of HIV epidemic.

(Refer Slide Time: 01:00)



Now, if you look at the slide the history of TB drug discovery has originated way back in 1940. And over the period of years till 1960 there has been a group of drugs discovered and brought into use.

Now, after 1960 till 2010 we do not find any orange dots the orange dots denotes the time period when new drugs been discovered. So, there has been a paucity of new drug discovery in the last 40 years, 40 to 50 years.

(Refer Slide Time: 01:27)


Main activity of ATT

Bactericidal activity	Sterilizing activity
Target actively growing bacteria through the inhibition of cell processes	Ability to kill persists and eliminate latent or "dormant" bacteria
Does not determine the length of treatment	Determines duration of treatment

Now, the main activity of antituberculosis treatment is bimodal one it is a bactericidal activity, other one being the sterilizing activity. The bactericidal activity mainly targets the actively growing bacteria by inhibiting the cell process, now this does not determine the length or duration of treatment.

While the sterilizing activity which is the ability of the drug to kill the persistent or eliminate the latent bacilli, or the dormant bacteria. This determines the duration or the length of the treatment for antituberculosis therapy.

(Refer Slide Time: 01:58)



As we know the anti TB drug action basically acts on 2 types of bacteria, one the rapidly multiplying other one the persister or the slowly multiplying organisms. All the first line drugs isoniazid, rifampicin, streptomycin, ethambutol, and pas they act on the rapidly multiplying bacteria in the extracellular phase.

The rifampicin, and pyrazinamide these two drugs will act on the slowly multiplying organisms or the persisters. These persisters are responsible for the development of relapse among treated tuberculosis patient. Unfortunately we do not have any drugs as of today that acts upon the dormant bacilli.

(Refer Slide Time: 02:34)

Profile of New TB drugs
New TB drug pipeline

So, what are the profile of any drug that claims to have an anti TB activity?

(Refer Slide Time: 02:37)

Important desirable characteristics of a new anti-TB drug

Antimicrobial profile	Pharmacological profile	Safety profile
<ul style="list-style-type: none">• Good sterilizing activity• Shortened duration of Rx (≤ 4 mo)• low relapse rate ($\leq 5\%$)• Good bactericidal activity• High cure rate ($\geq 95\%$)• No cross-resistance with current drugs (especially rifampicin and isoniazid)• Significant post-antibiotic effect (preferably ≥ 12 h)• Narrow antibacterial spectrum• Potential immunomodulation	<ul style="list-style-type: none">• Good formulation stability under field conditions• Good oral bioavailability ($\geq 90\%$)• Ready delivery by multiple systems/ channels• Absence of drug-drug interactions (both among ATT drugs and others)• Good lung penetration• Long elimination half-life (for once-daily or less frequent dosing)• Limited protein binding (preferably $\leq 50\%$)	<ul style="list-style-type: none">• No genotoxicity/ mutagenicity• Good clinical tolerance and absence of toxicity• Affordable

Expert Opin. Emerging Drugs (2011) 16(1):1-21

So, there are certain desirable characteristic given up for anti TB drug which includes antimicrobial profile, pharmacological profile, and the safety profile. Antimicrobial profile looks at a sterilizing activity, the bactericidal activity the presence, or absence of cross assistance with other drugs.

The drug should also have good formulation and stability in the field conditions, it should also have a good oral bioavailability and easily deliverable by multiple systems.

Most important these drug should also have no drug interactions when given along with other drugs, these drugs claiming to have anti TB activity should have good lung penetrations and long elimination half life. We are also looking at the safety profile of these drugs including good clinical tolerance, absence of toxicity, at the same time affordable at a low cost.

(Refer Slide Time: 03:27)



The image shows a woman in a saree presenting a slide. The slide content is as follows:

Manage TB


ICMR - National Institute for Research in Tuberculosis (NIRT)
www.nirt.res.in

Approach to new anti-TB drug development

- repurposing of old drugs
- re-engineering of existing antibacterial compounds
 - delamanid, PA-824, TBA-354, SQ109, oxazolidinone (linezolid & analogues)
- discovery of new compounds

Now, approach to new anti TB drug development can be threefold; one we can repurpose already existing old drugs or reengineer existing antibacterial compounds and look for the presence of the profile that we saw in the previous slide. For example, like drugs like the delamanid PA 824, the third one is a discovery of newer compounds.


(Refer Slide Time: 03:48)



The global TB drug pipeline various drugs were tried in the last many years for the last 40 to 50 years. Few of the drugs have been shortlisted and they have entered the phase 2, and phase 3 of clinical trials. Most important drugs that have entered the phase 2, phase 3 clinical trials include bedaquiline and delamanid. Various types of fluoroquinolones namely levofloxacin and moxiflox, repurpose drugs include linezolid and clofazimine.

Now, high dose rifampicin and rifapentine have also entered the phase three clinical trial for using in drug sensitive as well as drug resistant TB; Combination of drugs like bedaquiline and linezolid have also entered various phases of clinical trials to look for the efficacy in drug resistant TB.

(Refer Slide Time: 04:33)



The mechanism of a newer drugs the slide here shows the mechanism of action all drugs but I would like to concentrate on mechanism of newer anti TB drugs. For example, the delamanid PA 824 they inhibit a cell wall synthesis and in turn cell respiration. The newer drug bedaquiline inhibits the ATP synthase.

Now, this is something new mode of action that is coming into the pipeline, also have the fluoroquinolones which acts for inhibiting the DNA synthesis. We also have other drugs which are either in phase 1, or phase 2 clinical trial looking at the targeting outer membrane of and the cell respiration of the mycobacterium.

(Refer Slide Time: 05:15)

Approved new drugs for use in TB

S.No	Name of Drug	Approval year	Indication	RNTCP
1	Bedaquiline	FDA - December 2012	As part of combination therapy to treat adults with MDR PTB when other alternatives are not available	Bedaquiline Conditional Access Program (CAP) - launched in 6 sites in 2016
2	Delamanid	EU - April 2014 WHO - 2014 Conditional recommendation very low confidence in estimates of effects	As part of combination therapy to treat adults with MDR PTB	Delamanid - RNTCP PMDT - 2017

[Int J Appl Basic Med Res.](#) 2013; 3(1): 1-2.; [WHO/HTM/TB/2014.23_eng.pdf](#);; [Drugs.](#) 2014 Jun;74(9):1041-5.

Of all the drugs that I showed you in the previous slides 3 or 4 drugs have entered into the market and have been given accelerated approval to be used in programs in the national programs, two such drug are bedaquiline, and delamanid. Bedaquiline has been recommended to be used as part of combination therapy to treat adults with MDR pulmonary TB, when there is no other alternative available.

Delamanid again has been recommended by WHO as well as European, union as part of combination therapy to treat adults with multidrug resistant pulmonary TB. Both these drugs have been introduced into the into our national TB control program as well as PMDT, as of 2016 and 2017 respectively.


(Refer Slide Time: 06:00)

Manage TB

ICMR - National Institute for Research in Tuberculosis (NIRT)
www.nirt.res.in

Bedaquiline (BDQ)

- Bedaquiline (BDQ):
 - new class of drug - Diarylquinoline
 - specifically targets Mycobacterial ATP synthase, an enzyme essential for the supply of energy to *M.tb*
- Strong bactericidal and sterilizing activities
- Highly bound to plasma proteins & hepatically metabolized
- Drug has an extended half-life : 5.5 months
- Reserved for use in scenarios when an effective regimen cannot otherwise be provided



If we look at bedaquiline the newer anti TB drug this belongs to new class of drug called diarylquinoline. It specifically targets a mycobacterial ATP synthase, and enzyme essential for the supply the energy to MTB. This drug has both bactericidal as well as sterilizing activity this is highly bound to plasma protein and hepatically metabolized.

Drug has an extended half life of five and a half months it is reserved for use it scenarios for an effective regimen cannot be otherwise made to treat a multidrug resistant Tuberculosis.



(Refer Slide Time: 06:29)

Manage TB

ICMR - National Institute for Research in Tuberculosis (NIRT)
www.nirt.res.in

Bedaquiline: Dosage


- Week 0-2: BDQ 400 mg daily (4 tablets of 100 mg x all 7 days) + OBR
- Week 3-24: BDQ 200 mg (2 tablets of 100 mg) 3 times per week (with at least 48 hours between doses) for a total dose of 600 mg per week + OBR
- Week 25 (start of month 7) to end of treatment: Continue other second-line anti-TB drugs only as per RNTCP recommendations



Bedaquiline is available as 100 milligram tablets it is recommended in the dose of 400 milligrams daily for the first 2 weeks. It is given us 4 tablets of 100 milligram all 7 days along with the optimized background regimen. Subsequently from week 3 to week 24 bedaquiline 200 milligram is given as 2 tablets of 100 milligram, 3 times per week at least 48 hours apart between the doses, for a total dose of 600 milligram per week along with optimized background regimen.

At the end of week 24 bedaquiline stopped from week 25th onwards continue rest of the drugs of second line anti TB drug as per the RNTCP recommendation. Bedaquiline is available as oral tablets it has to be taken immediately after food consumption, it is swallowed whole and it is not advisable to break the tablets into two. RNTCP PMDT has come out with guidelines for the use of bedaquiline through conditional access program in the management of drug resistant TB in the country.

(Refer Slide Time: 07:32)



Delamanid

- Dihydro-nitroimidazoxazole derivative
- Acts by inhibiting the synthesis of mycobacterial cell wall components, methoxy mycolic acid and ketomycolic acid
- Potent antibacterial activity against drug-susceptible and drug-resistant strains of *M. tb*
- Half-life is 38 hrs
- Recommended dosage - 100mg twice daily
- To be taken along with food since the absorption gets better with food

ICMR - National Institute for Research in Tuberculosis (NIRT)
www.nirt.res.in

Manage TB

The second drug is delamanid delamanid belongs to the nitroimidazole group of drugs. It acts for inhibiting the synthesis of mycobacterial cell wall, the methoxy mycolic acid and the ketomycolic acid. It again is a potent antibacterial drug it acts against both drug acceptable as well as drug resistant strains of M TB. Unlike bedaquiline, its half life is only for 38 hours.

The recommended dosing is 100 milligram twice daily. This drug has to be taken along with food since absorption of the drug is better with food intake.

(Refer Slide Time: 08:06)

Manage TB

ICMR - National Institute for Research in Tuberculosis (NIRT)
www.nirt.res.in

Delamanid for MDR-TB

MDR-TB patients in whom delamanid may have a particular role include those with:

- higher risk for poor outcomes (eg. drug intolerance or contraindication, extensive or advanced disease);
- additional resistance to Fluoroquinolones or injectable drugs;
- XDR-TB

The use of delamanid in the treatment of multidrug-resistant tuberculosis
Interim policy guidance

World Health Organization

WHO has come up with a guideline for the use of delamanid in the treatment of multidrug resistant TB, especially individuals with higher risk for poor outcome like drug intolerant or extensively advanced case of drug resistant TB.

(Refer Slide Time: 08:21)


Manage TB

ICMR - National Institute for Research in Tuberculosis (NIRT)
www.nirt.res.in

Adverse effects of new anti-TB drugs

Drug	Adverse effects
Bedaquiline	<ul style="list-style-type: none">• Nausea, vomiting, diarrhea• Headache, dizziness• Q-Tc prolongation• Myalgia, Arthralgia• Hepatic - Increase transaminases
Delamanid	<ul style="list-style-type: none">• Nausea, vomiting, dizziness• Q-Tc prolongation


WHO/HTM/TB/2014.11



Both bedaquiline and delamanid have class adverse effect. Basically they cause of course, nausea vomiting like the other antituberculosis drugs has been used for drug resistant TB. Most important adverse event here is Q-Tc prolongation, both of them have

an cardiac effect and Q-Tc prolongation to be watched for when a individual is on either bedaquiline or delamanid.

(Refer Slide Time: 08:42)




Manage TB

ICMR - National Institute for Research in Tuberculosis (NIRT)
www.nirt.res.in

Pretomanid (PA 824)

- Nitroimidazole
- Active against sensitive and resistant *M. tb*
- Promising results in preclinical and clinical studies
- Forms part of a novel regimen (PaMZ) PA-824, moxifloxacin, pyrazinamide (PMZ) regimen
- Phase II study in MDR TB patients



The third newer drug is protom pretomanid, now this also bigger belongs to nitroimidazole group. It is active against both drug sensitive as well as drug resistant tuberculosis, it has shown a promising results both in preclinical as well as clinical studies; Moving on from individual newer drugs to drug regimen.

(Refer Slide Time: 08:57)



Manage TB

ICMR - National Institute for Research in Tuberculosis (NIRT)
www.nirt.res.in

New anti-TB treatment regimens in clinical development



(Refer Slide Time: 09:02)

Short course regimens for DSTB

Study	Regimen	Duration	Result
ReMox	2 MRHZ/ 2 MRH 2 MREZ/ 2 MR 2 RHZE/ 4 RH	4 months	Failed to show non-inferiority vs 6-month regimen
Oflotub	2 GRHZ/ 2 GHR 2 RHZE/ 4 RH	4 months	
Rifaquin	Moxifloxacin	4 months	
NIRT study	2 MRHZE/2 MRH, 2 MRHZE/2 MRH Thrice-weekly, 2 MRHZE /2 MRHE Thrice-weekly 2 ERHZ Thrice-weekly /4 RH Thrice-weekly	4 months	Shows promising results


Warnr DF et al. NEJM 2014

So, there are 4 new studies which is looked at the combination of fluoroquinolones along with rifa rifampicin, isoniazid, and pyrazinamide for a period of 4 months, remox oflotub and rifaquin studies where ethambutol was replaced with moxifloxacin or gatifloxacin for a period of 4 months.

In remox ethambutol has been replaced with moxifloxacin, and oflotub gatifloxacin replaces ethambutol. Rifaquin is another study where moxifloxacin also was used. All the studies have failed to show success rate beyond 6 month of regimen.

Unlike the three studies published NIRT has done a study where they have replaced moxi where they have added moxifloxacin, along with ethambutol for a period of 4 months. It was used both daily as well as in thrice weekly regimen patients were followed up for a period of 24 months and this result, has this study has shown promising results.

(Refer Slide Time: 09:54)



The early culture conversion was seen with moxifloxacin containing regimen. This graph here shows the red line is a control regimen of 6 month duration, the blue line is the moxifloxacin containing regimen of 4 months duration.

And you look at the culture conversion at the end of 2 months, the culture conversion with moxifloxacin containing regimen is around 95 percent as compared to 80 percent with the control regimen. We are awaiting the results of the long term results of moxifloxacin containing regimen which will be published very soon that is the end of session 1.

Thank you.